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AbstrACt
Objectives To provide a contemporary description of 
complementary medicine (CM) product use in Australia.
Design Cross-sectional survey.
setting Online.
Participants A nationally representative sample (n=2019) 
of the Australian adult population.
Primary and secondary outcome measures Primary 
outcomes measures included the use and type of CM 
products used, and source of recommendation. Secondary 
measures included disclosure of CM product use to health 
practitioners, concomitant use of pharmaceuticals and 
predictors of use.
results Prevalence of CM product use was 50.3%, 
with the most frequently used being vitamin and mineral 
supplements (VMSs; 47.8%) and homoeopathic medicines 
the least used (6.8%). A majority of respondents using CM 
products were also using pharmaceutical products, and 
small but significant associations were found between 
the use of CM products and pharmaceuticals (p<0.05). 
Small statistically significant associations were found 
between use of vitamin products and disclosure of use to 
general practitioners (GPs; Cramer's V=0.13, p=0.004) and 
hospital doctors (Cramer’s V=0.11, p=0.04), and between 
use of herbal medicines and disclosure to both GPs 
(Cramer’s V=0.11, p=0.02) and hospital doctors (Cramer’s 
V=0.12, p=0.03). Women, those with higher education and 
those with no private health insurance were more likely 
to use CM products (p<0.05), while those without chronic 
conditions were less likely to use CM products (p<0.05) 
(χ2(29)=174.70, p<0.001).
Conclusions The number of Australians using CM 
products has remained relatively stable and substantial 
for nearly two decades. The majority of CM use relates 
to VMSs. Given the number of Australians using both CM 
products and pharmaceutical medicines, it is important 
to evaluate the potential clinical implications of such 
practices to ensure safe, effective and coordinated health 
policy and patient care.
IntrODuCtIOn
The use of natural products—a range 
of products not traditionally associated 
with the medical profession or medical 
curriculum—is substantial across most coun-
tries.1 2 The titles employed to refer to such 
products vary between countries depending 
on the respective regulatory frameworks for 
medicines and food. The title ‘food supple-
ments’ is used in the UK, ‘traditional herbal 
medicine’ and ‘health supplements’ in China 
and parts of South and South East Asia, and 
the title ‘complementary medicines’ (CMs) is 
used in Australia. The Australian Department 
of Health is responsible for the regulation 
of CMs in Australia which includes vitamin 
and mineral supplements (VMSs), herbal 
and botanical medicines, homoeopathic 
preparations and aromatherapy oils. We have 
included all these elements in our defini-
tion of CMs to reflect this wider Australian 
context.3 
It is important to note that the practices 
and products that constitute CM may differ 
within different regions. These differences 
are considered within the WHOs defini-
tion that states ‘The terms "complementary 
medicine" or "alternative medicine" refer 
to a broad set of healthcare practices that 
are not part of that country’s own tradition 
strengths and limitations of this study
 ► This study involves a large sample of adults who 
were representative of the Australian population for 
age, gender and demographic location.
 ► The questionnaire includes validated instruments 
that are widely used to measure health status.
 ► The prevalence of complementary medicine 
(CM)  recommendations by Australian healthcare 
professionals are captured.
 ► Due to the cross-sectional design, we could not de-
termine causal relationships with CM use.
 ► The data are at risk of recall bias based on partici-
pant self-report of items related to the previous 12 
months.
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or conventional medicine and are not fully integrated 
into the dominant healthcare system’.4 This definition 
has been adopted in this study and accommodates a 
plethora of CM prescribing scenarios and contexts 
involving different health professionals including 
doctors and pharmacists.4–6 Furthermore, the prescrip-
tion and recommendation of CMs including vitamins 
by doctors and pharmacists in the Australian context is 
not systematic or formally directed7 8 nor is it included 
in any substantial way in the medical curriculum of any 
Australian medical school.7 In line with this definitional 
approach, cultural context and previous Australian 
studies,9–12 we have appropriately included vitamins in 
our CM definition. Importantly, our inclusion of vita-
mins in our CM definition is in keeping with the Austra-
lian health regulatory framework for CM.3
According to a Roy Morgan report, Australian 
consumers spent over $AU550 per capita on CMs in 2016, 
which was an increase from $AU472 from the previous 
5 years.13 A 2009 study identified 43.6% of 4500 Austra-
lians over the age of 50 years as consuming at least one 
CM product in the previous 24-hour period, and of these, 
86% were currently being treated with pharmaceutical 
medicines.10 More recent data show Australians spend 
more out of pocket contribution to CM products than 
to pharmaceutical medicines.14 Although very dated, 
the ‘latest’ peer-reviewed published data obtained from 
a nationally representative sample of Australians esti-
mated that the annual CM product expenditure was 
A$1.86 billion (US$1.41 billion) on CMs (excluding prac-
titioner visits).9
People use CM products as part of their self-care and 
make informed decisions about their use.2 15 However, 
reports suggest that a potentially substantial portion of 
people living with serious health conditions do not tell 
their medical doctors about their CM use.16–18 Reasons 
provided for not disclosing CM use are as follows: they 
did not think it is relevant, that CM practices and prod-
ucts are safe, the doctor would not know about CM and/
or that they would be negatively judged for choosing to 
use CM.16–18
Representative surveys of Australian adults use of CMs 
are over a decade old rendering the frequently cited 
prevalence, sociodemographic and economic data as 
possibly no longer accurate and in some cases obtained 
from narrow sample populations.9 19 In addition, there is 
limited current data about the health of Australians who 
are taking CM products and their decisions to disclose 
their CM product use to healthcare practitioners.2
In response, the study reported in this paper aimed to 
provide a contemporary analysis of CMs use (including 
VMSs) drawn from a representative sample of the Austra-
lian adult population. The primary objective of this study 
was to evaluate the prevalence and types of CM products 
used and the predictors of use.
MethODs
study design
A cross-sectional online survey was administered to 2025 
Australian adults representative of the Australian popu-
lation. Representativeness was defined as matching the 
study sample population for distribution by age, gender 
and state of residence against the Australian Bureau of 
Statistics population demographic data.
recruitment
Purposive convenience sampling was used to recruit 
participants from an existing database of Australian 
adults who had expressed interest in participating in 
research (Qualtrics). An email invitation to participate in 
the study was sent to members of the database. The survey 
took approximately 15 min to complete, and participants 
received a small financial remuneration based on time to 
complete. Ethics approval was provided by the Human 
Research Ethics Committee at Endeavour College of 
Natural Therapies (20170242) in accordance with the 
Declaration of Helsinki.
Patient and public involvement
This research was done without substantial patient 
involvement. Individuals without a research or healthcare 
background who were known to the research team were 
invited to comment on the survey instrument but not 
the study design and they were not consulted to develop 
patient-relevant outcomes or interpret the results. 
Patients were not invited to contribute to the writing 
or editing of this document for readability or accuracy. 
Patients will be enlisted for their help in the dissemina-
tion of the outcomes of this study.
Measurement
Demographic questions included gender, age, marital 
status, postcode of residence, highest level of educational 
qualification, employment status and level of financial 
difficultly currently experienced. Participants were also 
asked if they currently had a centre link (social security) 
healthcare card, and if they had private health insurance 
for a range of health services.
Health status
Participants were asked to indicate if they had been diag-
nosed or treated for a chronic illness in the previous 3 
years from a list of 30 chronic conditions, with the option 
to indicate an ‘other health condition’ and specify the 
condition, or ‘none of the above’ indicating they had not 
been diagnosed or treated for a chronic illness. One item 
from the Medical Outcomes Study Short Form-20 (SF-20) 
was used to assess perceived general health status that 
asked participants to rate their health status on a 5-point 
Likert scale ranging from excellent (1) to poor (5). The 
SF-20 is a widely used measure of health-related quality 
of life.20
CM use
Questions related to CM use were adapted from the 
International Complementary and Alternative Medicine 
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Questionnaire (I-CAM-Q). The I-CAM-Q was developed 
as a measure of CM health service and treatment use 
that could be used consistently across different popula-
tions that has been validated in a range of population 
samples.21 22 The I-CAM-Q necessitates country-specific 
items be added that are relevant to the population 
studied23; therefore, a number of changes were made to 
ensure validity of the I-CAM-Q in an Australian popula-
tion. Items from the I-CAM-Q used in this study related to 
CM product use including products used in the previous 
12 months, who prescribed them (eg, type of health prac-
titioner), and estimated total cost of each medicine type.
Pharmaceutical medicine use
A single item asked participants ‘Do you take prescrip-
tion medicine daily?’ requiring a dichotomous (yes, no) 
response. If answering yes to this question, participants 
were then asked: ‘What condition is the medicine taken 
to treat?’ requiring an open-ended response.
CM disclosure
Participants were questioned about their communication 
with healthcare professionals (HCPs) within the previous 
12 months. Specifically, they were questioned regarding 
their disclosure of CM use to their general practitioner 
(GP), specialist doctor, hospital doctor and/or pharma-
cist. There were four response options: ‘I told them about 
ALL complementary and alternative medicines I was 
using’, ‘I only told them about SOME of my complemen-
tary and alternative medicine use’, ‘I DID NOT tell them 
about my complementary and alternative medicine use’ 
and ‘I did not visit this type of health professional’.
Data analysis
The data were analysed using IBM SPSS Statistics 
Premium Edition V.22. The data were initially screened 
for disengaged and missing responses, which resulted in 
six respondents being removed as their responses were 
unreliable (ie, no variance or repeat patterns in the data), 
leaving 2019 participants in the final data set. Relevant 
variables were recoded to reflect a positive direction.
χ2 tests were used to examine the associations between 
categorical variables of interest and CM product use. 
Sociodemographic variables with an association p<0.2524 
or with theoretical importance were included in a logistic 
regression to identify significant predictors of CM product 
use.
Economic data were calculated based on the mean (and 
SD) of expenditure of CM products for all participants, 
and for CM product users only. The mean for all partici-
pants was then extrapolated to the Australian population 
based on the most recent census figures.25
results
Participant characteristics
The sociodemographic characteristics of participants are 
included in table 1. The majority of participants were 
women (n=1034), with three people identifying as ‘other’ 
gender, which is comparable to the Australian general 
population.25 The majority of participants (26.1%) 
were ≥60 years of age. New South Wales (29.7%) was the 
most common place of residence. The minority of partic-
ipants were those aged between 50 and 59 years (15.2%) 
and those residing in the Australian Capital Territory 
(1.4%). The majority of participants were either employed 
full time (31.6%) or not in the paid workforce (34%). The 
most commonly reported highest level of education was a 
trade/apprenticeship/certificate/diploma (33.8%), with 
the least common being less that year 12 (16.2%). Most 
participants were married (42.8%), which compared with 
1.4% in a same-sex and 10.9% in an opposite-sex de facto 
relationship.
Associations between sociodemographic variables and CM 
product use
χ2 tests of association revealed that gender, employment 
status, marital status, chronic health condition and private 
health insurance were all statistically significantly associ-
ated with CM product use with (see table 1 for summary 
statistics). People with private health insurance (PHI) 
were less likely to use CM products than those without. 
Cramer’s V showed that the strength of all significant 
associations was negligible (0.01) to small (16).26
expenses for each type of medicine use
Table 2 presents the summary of the expenditure of 
each type of medicine product reported in the previous 
12 months. Survey respondents spent an average of 
AUD$102.41 on prescription-only pharmaceuticals and 
$39.52 on over-the-counter pharmaceuticals. Mean 
expenditure on CM products varied across categories with 
the highest spend on VMSs (AUD$86.24 per CM product 
user) and the lowest spend on homeopathy (AUD$7.05 
per CM product user) and flower essences (AUD$4.94 
per CM product user). Extrapolation of this data to 
the Australian population indicates an annual spend of 
AUD$480 on CM products.
Prevalence of CM and pharmaceutical medicine use and 
source of prescription
A total of 1016 participants used any type of CM product 
(50.3%), which compared with 74.4% of participants who 
used prescription pharmaceuticals, and 66.8% who used 
over-the-counter pharmaceuticals. VMSs were the most 
frequently used CM product (47.8%) by participants, and 
were the most frequently prescribed by all types of health 
practitioners, and the most frequently self-prescribed. In 
contrast, homeopathic products were the least frequently 
used (6.8%), and the least frequently prescribed CM 
product by GPs, pharmacists, store assistants and least 
frequently self-prescribed. See table 3 for a summary of 
the frequency of each type of medicine use.
Table 3 shows that statistically significant associations 
were found between all types of medicine use with all 
sources of medicine prescription. For self-prescription, 
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Table 1 Participant sociodemographic characteristics and associations between CM product use 
Characteristic
Used CM products Total
P valueNo (n=1003) Yes (n=1016) (N=2019) 
Gender
  Female 444 (44.4) 590 (58.1) 1034 (51.2) <0.001
  Male 557 (55.6) 425 (41.9) 982 (48.6)
  Other* - - 3 (0.1)
Age (years) 
  18–29 281 (28) 231 (22.7) 512 (25.4) 0.08
  30–39 156 (15.6) 157 (15.5) 313 (15.5)
  40–49 170 (16.9) 192 (18.9) 362 (17.9)
  50–59 150 (15) 156 (15.4) 306 (15.2)
  60 and over 246 (24.5) 280 (27.6) 526 (26.1)
State 
  New South Wales 307 (30.6) 290 (28.5) 597 (29.6) 0.07
  Victoria 262 (26.1) 226 (22.2) 488 (24.2)
  Queensland 202 (20.1) 262 (25.8) 464 (23)
  South Australia 95 (9.5) 93 (9.2) 188 (9.3)
  Northern Territory 4 (0.4) 1 (0.1) 5 (0.2)
  Western Australia 95 (9.5) 104 (10.2) 199 (9.9)
  Tasmania 24 (2.4) 25 (2.5) 49 (2.4)
  Australian Capital Territory 14 (1.4) 15 (1.5) 29 (1.4)
Employment status 
  Full-time work 327 (32.6) 312 (30.7) 639 (31.6) 0.01
  Part-time work 167 (16.7) 203 (20) 370 (18.3)
  Casual/temp work 66 (6.6) 73 (7.2) 139 (6.9)
  Looking for work 112 (11.2) 73 (7.2) 185 (9.2)
  Not in the paid workforce 331 (33) 355 (34.9) 686 (34)
Marital status 
  Never married 320 (31.9) 264 (26) 584 (28.9) 0.001
  Married 394 (39.3) 470 (46.3) 864 (42.8)
  De facto (opposite sex) 126 (12.6) 94 (9.3) 220 (10.9)
  De facto (same sex) 11 (1.1) 18 (1.8) 29 (1.4)
  Separated/divorced/widowed 152 (15.2) 170 (16.7) 322 (16)
Highest qualification 
  Less than year 12 185 (18.4) 142 (14) 327 (16.2) <0.001
  Year 12 or equivalent 251 (25) 170 (16.7) 421 (20.9)
  Trade/apprenticeship/certificate/diploma 320 (31.9) 362 (35.6) 682 (33.8)
  University degree 247 (24.6) 342 (33.7) 589 (29.1)
General health status 
  Poor 68 (6.8) 96 (9.4) 164 (8.4) 0.07
  Fair 220 (21.9) 220 (50) 440 (21.8)
  Good 335 (30.7) 335 (33) 643 (31.8)
  Very good 287 (31) 287 (28.2) 598 (29.6)
  Excellent 78 (9.6) 78 (7.7) 174 (8.6)
Chronic health condition 
Continued
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the strongest associations were found with aromatherapy 
oils (Cramer’s V=0.58, p<0.001) and vitamins and mineral 
use (Cramer’s V=0.61, p<0.001). Unsurprisingly, the stron-
gest association for prescription pharmaceutical use was 
with GPs (Cramer’s V=0.72, p<0.001). The weakest asso-
ciation was found between use of over-the-counter phar-
maceuticals and CM practitioner prescription (Cramer’s 
V=0.06, p=0.009).
Associations between CM product use and pharmaceutical 
medicine use
The majority (>80%) of ingestible CM product (ie, herbal 
medicines, vitamin and nutritional supplements, home-
opathy, flower essences) users reported use of pharma-
ceutical medicines. All types of ingestible CM products 
were statistically significantly (p<0.05) associated with 
both over-the-counter and prescribed pharmaceutical 
medicine use, with the exception of the relation between 
flower essences and prescribed pharmaceuticals. The 
strength of associations ranged from negligible to small. 
See table 4 for χ2 test results.
CM use disclosure
χ2 tests of association were conducted between the use 
of each type of ingestible CM product and disclosure of 
use to health professionals to determine frequencies and 
percentages in people who used any type of CM product 
(n=1016). These analyses only found small statistically 
significant associations between the use of vitamin/nutri-
tional products and disclosure to both GPs (Cramer’s 
Characteristic
Used CM products Total
P valueNo (n=1003) Yes (n=1016) (N=2019) 
  Yes 576 (57.4) 738 (72.6) 1314 (65.1) <0.001
  No 427 (42.6) 278 (27.4) 705 (34.9)
Financial management 
  It is impossible/it is difficult all of the time 217 (21.6) 213 (21) 430 (21.3) 0.91
  It is difficult some of the time 375 (37.4) 391 (38.5) 766 (37.9)
  It is not too bad 352 (35.1) 348 (34.3) 700 (34.7)
  It is easy 59 (5.9) 64 (6.3) 123 (6.1)
Healthcare card 
  Yes 406 (40.5) 433 (42.6) 839 (41.6) 0.34
  No 597 (59.5) 583 (57.4) 1180 (58.4)
Private health insurance 
  Yes 558 (55.6) 470 (46.3) 1028 (50.9) <0.001
  No 445 (44.4) 546 (53.7) 991 (49.1)
*Excluded due to cell size count <5.
Table 1 Continued 
Table 2 Expenditure for each type of medicine use in the previous 12 months 





CM product user 
(n=1016)
Mean expense per 
person (n=2019)
Estimated CM product 
expense for Australian 
population (n=24 702 
900)
Pharmaceutical products
  Prescription-only pharmaceuticals $206 761.69 $122.44 $102.41 $3 024 623 076
  Over-the-counter pharmaceuticals $79 798.05 $52.39 $39.52 $1 294 184 931
CM products
  Western or Chinese herbal medicines $11 534.00 $11.24 $5.71 $277 660 596
  Vitamin/mineral supplements $88 297.20 $86.46 $43.73 $2 135 812 734
  Aromatherapy oils $10 381.00 $10.13 $5.14 $250 240 377
  Homeopathy $7239.00 $7.05 $3.59 $174 155 445
  Flower essences $5107.00 $4.94 $2.54 $122 032 326
  Total CM products $122 558.20 $119.82 $60.71  $2 959901 478
CM, complementary medicine.
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V=0.13, p=0.004) and hospital doctors (Cramer’s V=0.11, 
p=0.04), and between use of herbal medicines and disclo-
sure to both GPs (Cramer’s V=0.11, p=0.02) and hospital 
doctors (Cramer’s V=0.12, p=0.03). No association was 
found between any other type of product use and disclo-
sure to health practitioners. See table 5 for summary 
statistics.
Predictors of CM product use
The independent variables of gender, age, marital status, 
qualification, general health status, chronic health condi-
tion and private health insurance were included in a bino-
mial logistic regression predicting CM product use. The 
model was statistically significant, χ2(29)=174.70, p<0.001, 
and correctly classified 61% of cases. Gender, qualifica-
tion, chronic disease diagnosis and private health insur-
ance were statistically significant (p<0.05) predictors of 
CM product use (see table 6). Women had an increased 
odds of using CM product compared with men. Higher 
education levels were associated with an increased like-
lihood of CM product use compared with those with less 
than year 12 level education, with the exception of univer-
sity degree level. People with a chronic health condi-
tion were more likely to use CM products compared with 
those without a chronic health condition. Those without 
private health insurance were more likely to use CM prod-
ucts compared with those with PHI.
DIsCussIOn
This is the first study in over a decade to report the prev-
alence, characteristics and predictors of CM product use 
in a nationally representative population of Australians. 
We identified that 50.3% of Australians used some form 
of CM product in the previous 12 months. CM use in 
the general population has previously reported in 2006 
at 68.9% including both products and services.9 Unfor-
tunately, a direct comparison between our data and this 
previous study cannot be made as a number of CM in the 
older study could not be clearly categorised into either 
products or services. The consistency of these figures 
suggests that the use of CM products is an established 
feature of Australians’ healthcare choices.
The estimated annual expenditure on CM products by 
the adult Australian population in 2006 was A$1.86 billion,9 
which is higher than the estimated expenditure of 
AUD$480 million identified from our data. It is important 
to note, however, that the difference in expenditure is 
likely related to the difference in defining a CM product 
rather than a substantive difference in CM spending by 
the Australian population. As the previously published 
data did not specify which products were included in 
the final amount of expenditure, the variability between 
both studies is difficult to meaningfully quantify. Industry 
data from the Complementary Medicine Association for 
CM reports much higher sales revenue for CM products 
(AUD$4.7 billion); however, this includes domestic sales 
and international exports as well as other health products 
not included in our study, such as sports nutrition, meal 
replacements and weight loss products.27
VMSs were the most common CM product used by 
Australians (47%), which is comparable to 45% of Austra-
lians who reported using supplements in 2006.9 Other 
reports obtained from narrower samples of Australians 
within the last 20 years provide similar rates, reporting 
VMS use ranging from 47% to 53%.10 19 28 29 Both Xue et 
al9 and Morgan et al10 instructed participants to exclude 
medically prescribed nutrients such as iron and calcium 
when reporting their VMS use. This present study did 
not instruct participants to exclude medically prescribed 
nutrients. Nevertheless, VMS were the most common CM 
products prescribed by any type of healthcare professional 
in our study, which may be associated with the treatment 
of common medical conditions such as iron deficiency,30 
the use of calcium and vitamin D in the clinical manage-
ment of osteoporosis, vitamin D deficiency31 and specific 
VMS formulations for macular degeneration.32 33
Table 4 Associations between type of ingestible CM product used and pharmaceutical product use 
Type of CM product 
used
Used any CM product (n=1016)
Used prescribed pharmaceutical n (%) Used over-the-counter pharmaceutical n (%)
No Yes Total* p
Cramer’s 






No 151 (87.8) 674 (79.9) 825 (81.2) 0.02 0.08 181 (21.9) 644 (78.1) 825 (81.2) 0.002 0.10
Yes 21 (12.2) 170 (89) 191 (18.8) 23 (12) 168 (88) 191 (18.8)
Vitamin/mineral 
supplements
No 15 (30) 35 (70) 50 (4.9) 0.01 0.08 19 (38) 31 (62) 50 (4.9) 0.001 0.10
Yes 157 (16.3) 809 (83.7) 966 (95.1) 185 (19.2) 781 (80.8) 966 (95.1)
Homeopathy No 160 (18.2) 718 (81.8)) 878 (86.4) 0.006 0.09 199 (22.7) 679 (77.3) 878 (86.4) <0.001 0.16
Yes 12 (8.7) 126 (91.3) 138 (13.6) 5 (3.6) 133 (96.4) 138 (13.6)
Flower essences No 153 (17.7) 712 (82.3) 865 (85.1) 0.12 0.05 195 (22.5) 670 (77.5) 865 (85.1) <0.001 0.15
Yes 19 (12.6) 132 (87.4) 151 (14.9) 9 (6) 142 (94) 151 (14.9)
*Percentage of total number of participants using any CM product.
CM, complementary medicine. 
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Table 6 Predictors of complementary medicine product use 
Variable OR (95% CI) P value
Gender 
  Female 1.78 (1.46 to 2.18) <0.001
  Male – – 
Age (years) 
  18–29 – 0.55
  30–39 0.83 (0.59 to 1.17) 0.29
  40–49 0.80 (0.57 to 1.13) 0.21
  50–59 0.87 (0.63 to 1.19) 0.38
  60 and over 0.76 (0.56 to 1.06) 0.10
State 
  New South Wales – 0.21
  Victoria 0.87 (0.40 to 1.92) 0.73
  Queensland 0.77 (0.35 to 1.71) 0.52
  South Australia 1.12 (0.50 to 2.48) 0.79
  Northern Territory 0.92 (0.40 to 2.12) 0.85
  Western Australia 0.23 (0.02 to 2.54) 0.23
  Tasmania 1.02 (0.45 to 2.33) 0.96
  Australian Capital Territory 0.93 (0.35 to 2.48) 0.89
Employment status 
  Full-time work – 0.13
  Part-time work 1.08 (0.81 to 1.43) 0.61
  Casual/temp work 1.25 (0.93 to 1.68) 0.14
  Looking for work 1.18 (0.79 to 1.78) 0.42
  Not in the paid workforce 0.76 (0.52 to 1.10) 0.15
Marital status 
  Never married – 0.18
  Married 0.95 (0.68 to 1.33) 0.77
  De facto (opposite sex) 1.07 (0.81 to 1.42) 0.61
  De facto (same sex) 0.73 (0.50 to 1.07) 0.11
  Separated/divorced/widowed 1.43 (0.62 to 3.32) 0.40
Highest qualification 
  Less than year 12 – <0.001
  Year 12 or equivalent 0.53 (0.39 to 0.73) <0.001
  Trade/apprenticeship/certificate/diploma 0.51 (0.39 to 0.68) <0.001
  University degree 0.81 (0.63 to 1.05) 0.09
General health status 
  Poor – 0.31
  Fair 1.40 (0.86 to 2.26) 0.18
  Good 0.96 (0.65 to 1.41) 0.84
  Very good 1.12 (0.78 to 1.61) 0.53
  Excellent 0.99 (0.69 to 1.42) 0.95
Chronic health condition 
  No 0.52 (0.42 to 0.64) <0.001
  Yes – – 
Do you have PHI? 
Continued
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As reported by the participants in this study, VMS 
were the most commonly prescribed CM products by all 
healthcare providers, half of the VMS used were self-pre-
scribed. It is generally accepted and promoted by health 
authorities and health professionals, that eating a well-bal-
anced diet will provide adequate vitamin and minerals to 
prevent deficiencies.34 VMSs sold in Australia are required 
to carry a ‘warning’ on their labels that reads ‘vitamin/
mineral supplements should not replace a balanced 
diet’.3 Although the reasons why so many Australians 
use VMSs was not the focus of this study, it is important 
that additional research is conducted to identify drivers 
of VMS use. Possible reasons for such high use may be 
associated with the substantial number of Australians not 
meeting the recommended intake of foods high in vita-
mins and minerals and their high intake of ‘discretional’ 
foods.35 The Australian Bureau of Statistics 2015 National 
Health Survey reported that just less than half (49.8%) of 
Australian adults meet the Australian Dietary Guidelines 
for recommended daily serves of fruit, only 7% meet the 
guidelines for serves of vegetables, and 5.1% meet both 
guidelines.35 Other research has reported inadequate 
dietary intakes and/or deficiencies of specific nutrients 
among children, pregnant women and adolescences for 
iron30 zinc,36 calcium, magnesium, vitamin D and folic 
acid.37 Whether the high use of VMS among Australians 
is associated with an attempt to compensate for poor food 
choices is an area that requires public health attention. Of 
equal importance, is the need to understand if and why 
well-nourished Australians supplement their diet with 
VMSs. While there is some evidence to suggest that the 
long-term use of multi-VMSs for up to 10 years in healthy 
populations is likely to be safe, formulations vary and 
there are safety concerns for specific populations taking 
specific nutrients; for example, smokers and beta carotene 
use has been associated with increasing the risk of lung 
cancer.38 Other research is currently being conducted to 
evaluate the efficacy and safety of more clearly defined 
VMS formulations in specific populations.39
CM product use being greater among women, those in 
full-time employment, and those with a higher level of 
education in our study is consistent with previous find-
ings.2 9 29 However, our finding that those with private 
health insurance were less likely to use CM products 
compared with those with private health insurance differs 
from these previous studies.9 29 40 While highly speculative, 
there may be an association with the rising costs of private 
health insurance premiums in Australia41 and consumers 
allocating more of their income on health maintenance 
and preventative strategies as a ‘surrogate’ to private 
health insurance. The efficacy of VMS in disease preven-
tion and health maintenance is unclear and controver-
sial resulting in large-scale research currently being 
undertaken.39
Having a diagnosis of one or more chronic illnesses 
also increased the likelihood of CM product use and CM 
product users were likely (>80%) users of both over-the-
counter and prescription pharmaceuticals. Given that 
self-prescribing of CM products is the most common 
method leading to use, it is important that healthcare 
professionals caring for individuals with chronic disease 
inquire about CM product use and monitor for any 
potential disease–CM interactions and drug–CM product 
interactions, especially with regards to herbal medicines. 
The likelihood of having a chronic illness increases with 
age and so does pharmaceutical medicine use.10 While 
evidence-based resources aimed at practitioners are avail-
able to guide appropriate and safe use of CMs,42 well-es-
tablished evidence based on human studies is limited. 
Available evidence is largely based on theory obtained 
from animal studies with individual case reports currently 
used to calculate likely risks.43 This being said, it is well 
established that short-acting pharmaceutical medicines 
used for serious diseases ,such as the use of digoxin for 
heart disease and chemotherapeutic agents for cancer, 
may result in serious interactions when used concurrently 
with some CMs, resulting in possible therapeutic failure 
or drug-related toxicity.44
The finding that both users of VMS and herbal medi-
cines were more likely to disclose their use to their GPs 
and hospital doctors than to pharmacists and specialists is 
encouraging. However, overall the number of those that 
never disclose their herbal medicine use (18%) is similar 
to that reported in 2006 where 17.9% participants never 
informed their doctors about any CM use.9 However, 
data obtained in 2012 reporting Australians’ disclosure 
to HCPs about CM use reported that only 47% to 60% 
informed their health professionals.45
Given the majority of CM products and over-the-counter 
pharmaceutical and prescription medicines are accessed 
through pharmacy outlets, further developments within 
the profession are required to help encourage CM 
product users to discuss such use with their pharmacist.8 
The reasons for a lower disclosure rate about CM use to 
medical specialists and pharmacists compared with other 
healthcare professionals in this study is unclear. Specula-
tively, there may be an association with earlier reports that 
suggest such healthcare providers feel they do not have 
adequate training or education to be able to engage in 
discussions about CMs.7 16 46 47
Variable OR (95% CI) P value
  No 1.33 (1.09 to 1.62) 0.01
  Yes – – 
  Constant 1.30 0.57
Table 6 Continued 
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This study presents the first nationally representative 
data in over 10 years regarding the use of CM prod-
ucts in the Australian population. Interpretation of the 
findings, however, must be contextualised to the study’s 
limitations. The study may be vulnerable to random error 
due to sampling bias; however, as the participants have 
been verified as nationally consistent based on a range of 
sociodemographic variables, this is likely to have minimal 
impact on the outcome of our analysis. The data are also 
at risk of recall bias based on participant self-report of 
items related to the previous 12 months. This is particu-
larly the case for the economic data, which should only be 
considered estimates of true values. However, the instru-
ment used in this study is informed by increased rigour 
in health services research methodology and advances 
in knowledge regarding CM use globally over the last 
decade, and as such offers the most robust and contem-
porary view of the topic than has been available in recent 
years.
COnClusIOns
Overall CM product use in Australia has remained stable 
over the last 10 years and can be confirmed as an estab-
lished component of many Australians healthcare choices. 
This highlights the need for all health professionals 
providing care to the Australian population to engage 
more meaningfully in the role, value and implications of 
this use. Pharmacists and medical doctors, in particular, 
need to ensure their knowledge of ingestible CM prod-
ucts is up-to-date and evidence-based so they can provide 
accurate and relevant information to the Australian 
community seeking their care. Future research is encour-
aged to focus on the reasons a substantial number of 
Australian are using VMS, the efficacy in ‘supplementing’ 
inadequate dietary nutrient intakes and the safety of long-
term and concurrent use with pharmaceutical medicines.
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